US Drug Recall Register

FDA Drug Recalls

2,661 recalls, newest first

Class II · Moderate risk Ongoing

Erin's Faces

Reason cGMP deviations

Kabana Skin Care D-0513-2025
Class II · Moderate risk Ongoing

B Natural Organics

Reason cGMP deviations

Kabana Skin Care D-0512-2025
Class II · Moderate risk Ongoing

chlorproMAZINE Hydrochloride Tablets

Reason CGMP deviations: presence of N-Nitroso-Desmethyl Chlorpromazine impurity above the recommended interim limit.

Glenmark Pharmaceuticals Inc., USA NDC 68462-864-01 D-0309-2025
Class II · Moderate risk Ongoing

Ciprofloxacin Ophthalmic Solution USP

Reason Defective container: Unable to get the solution out of the bottle as the spike of the cap was lodged in the nozzle of the product bottle

FDC Limited NDC 69315-308-05 D-0282-2025
Class II · Moderate risk Ongoing

Duloxetine D/R

Reason CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity above the proposed interim limit.

Direct Rx NDC 61919-0482-30 D-0568-2025
Class II · Moderate risk Ongoing

Duloxetine D/R

Reason CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity above the proposed interim limit.

Direct Rx NDC 61919-422-30 D-0567-2025
Class II · Moderate risk Ongoing

Sofosbuvir and Velpatasvir

Reason Defective Container: blister packs not properly sealed resulting in tablets being loose in the carton.

Asegua Therapeutics LLC NDC 72626-2701-1 D-0313-2025
Class II · Moderate risk Ongoing

Levothyroxine Sodium Tablets

Reason Super-Potent Drug: Out of specification potency results were obtained.

Mylan Institutional, Inc. NDC 51079-443-20 D-0291-2025
Class II · Moderate risk Ongoing

Levothyroxine Sodium Tablets

Reason Super-Potent Drug: Out of specification potency results were obtained.

Mylan Institutional, Inc. NDC 51079-445-20 D-0290-2025
Class II · Moderate risk Ongoing

La Roche-Posay Laboratoire Dermatologique Effaclar Duo Dual…

Reason cGMP Deviations: The recall was initiated due to detected trace levels of benzene in a specific lot of this product lot (MYX46W), however out of an abundance of caution, the firm voluntarily recalled all La Roche-Posay Effaclar Duo Dual Action Acne Treatment lots.

L'Oreal USA D-0419-2025
Class II · Moderate risk Ongoing

La Roche-Posay Laboratoire Dermatologique Effaclar Dermatological Acne System

Reason cGMP Deviations: The recall was initiated due to detected trace levels of benzene in a specific lot of this product lot (MYX46W), however out of an abundance of caution, the firm voluntarily recalled all La Roche-Posay Effaclar Duo Dual Action Acne Treatment lots.

L'Oreal USA D-0418-2025
Class II · Moderate risk Ongoing

Testosterone Gel 1%

Reason Presence of foreign substance: Presence of Benzene.

Strides Pharma, Inc. NDC 64380-152-02 D-0294-2025
Class II · Moderate risk Ongoing

Testosterone Gel 1%

Reason Presence of foreign substance: Presence of Benzene.

Strides Pharma, Inc. NDC 64380-151-02 D-0293-2025
Class II · Moderate risk Ongoing

Prasugrel Tablets

Reason Failed Dissolution Specifications

Golden State Medical Supply Inc. NDC 51407-444-30 D-0287-2025
Class II · Moderate risk Ongoing

Duloxetine Delayed-Release Capsules

Reason CGMP Deviations: Presence of N-nitroso-duloxetine impurity above recommended interim limit.

Rising Pharma Holding, Inc. NDC 57237-018-99 D-0277-2025